Understanding and preventing type 1 diabetes through the unique working model of TrialNet
Open Access
- 2 August 2017
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 60 (11) , 2139-2147
Abstract
Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (TrialNet)
- the Eunice Kennedy Shriver National Institute of Child Health and Human Development (TrialNet)
- JDRF (TrialNet)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK06)
This publication has 30 references indexed in Scilit:
- Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetesDiabetologia, 2017
- Characterization of asthma endotypes: implications for therapyAnnals of Allergy, Asthma & Immunology, 2016
- Blood-based signatures in type 1 diabetesDiabetologia, 2015
- β cell ER stress and the implications for immunogenicity in type 1 diabetesFrontiers in Cell and Developmental Biology, 2015
- Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 DiabetesDiabetes, 2014
- Molecular Signatures Differentiate Immune States in Type 1 Diabetic FamiliesDiabetes, 2014
- B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year ResultsDiabetes Care, 2014
- Development of Autoantibodies in the TrialNet Natural History StudyDiabetes Care, 2011
- Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials NetworkAnnals of the New York Academy of Sciences, 2008
- ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIESThe Lancet, 1974